Home Featured Page 257

Featured

Latest

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

More than 80% of Americans report one or more symptoms of...

The Impact of Specific Genes on Cannabis Use Disorder

IntelGenx Announces Initial Closing of atai Investment

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop...

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture...

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug...

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of...

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase...

BetterLife Announces Closing of a Non-Brokered Private Placement

Entheon Biomedical Corp. Provides Corporate Update

1...256257258...306 Page 257 of 306

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

More than 80% of Americans report one or more symptoms of...

The Impact of Specific Genes on Cannabis Use Disorder

IntelGenx Announces Initial Closing of atai Investment

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop...

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture...

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug...

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of...

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase...

BetterLife Announces Closing of a Non-Brokered Private Placement

Entheon Biomedical Corp. Provides Corporate Update

EDITOR PICKS

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY